Top

BMC Nephrology

Published in:

Open Access 01-12-2018 | Research article

Cortical and trabecular bone are equally affected in rats with renal failure and secondary hyperparathyroidism

Authors: Nikita M. Bajwa, Cheryl P. Sanchez, Richard C. Lindsey, Heather Watt, Subburaman Mohan

Published in: BMC Nephrology | Issue 1/2018

Abstract

Background

Changes in mineral metabolism and bone structure develop early in the course of chronic kidney disease and at end-stage are associated with increased risk of fragility fractures. The disruption of phosphorus homeostasis leads to secondary hyperparathyroidism, a common complication of chronic kidney disease. However, the molecular pathways by which high phosphorus influences bone metabolism in the early stages of the disease are not completely understood. We investigated the effects of a high phosphorus diet on bone and mineral metabolism using a 5/6 nephrectomy model of chronic kidney disease.

Methods

Four-week old rats were randomly assigned into groups: 1) Control with standard diet, 2) Nephrectomy with standard rodent diet, and 3) Nephrectomy with high phosphorus diet. Rats underwent in vivo imaging at baseline, day 14, and day 28, followed by ex vivo imaging.

Results

Cortical bone density at the femoral mid-diaphysis was reduced in nephrectomy-control and nephrectomy-high phosphorus compared to control rats. In contrast, trabecular bone mass was reduced at both the lumbar vertebrae and the femoral secondary spongiosa in nephrectomy-high phosphorus but not in nephrectomy-control. Reduced trabecular bone volume adjusted for tissue volume was caused by changes in trabecular number and separation at day 35. Histomorphometry revealed increased bone resorption in tibial secondary spongiosa in nephrectomy-control. High phosphorus diet-induced changes in bone microstructure were accompanied by increased serum parathyroid hormone and fibroblast growth factor 23 levels.

Conclusion

Our study demonstrates that changes in mineral metabolism and hormonal dysfunction contribute to trabecular and cortical bone changes in this model of early chronic kidney disease.

USRDS annual data report. Epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2015.

Lau WL, Linnes M, Chu EY, Foster BL, Bartley BA, Somerman MJ, et al. High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease. Nephrol Dial Transplant. 2013;28(1):62–9. https://doi.org/10.1093/ndt/gfs333.CrossRefPubMed

Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res. 2013;28(8):1811–20. https://doi.org/10.1002/jbmr.1916.CrossRefPubMedPubMedCentral

Ott SM. Bone histomorphometry in renal osteodystrophy. Semin Nephrol. 2009;29(2):122–32. https://doi.org/10.1016/j.semnephrol.2009.01.005.CrossRefPubMed

Spasovski GB, Bervoets AR, Behets GJ, Ivanovski N, Sikole A, Dams G, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dialysis, transplantation. 2003;18(6):1159–66.CrossRef

Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, Cadarette SM, et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014;86(4):810–8. https://doi.org/10.1038/ki.2013.547.CrossRefPubMed

Miller MA, Chin J, Miller SC, Fox J. Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone. 1998;23(3):257–66.CrossRefPubMed

Shipov A, Segev G, Meltzer H, Milrad M, Brenner O, Atkins A, et al. The effect of naturally occurring chronic kidney disease on the micro-structural and mechanical properties of bone. PLoS One. 2014;9(10):e110057. https://doi.org/10.1371/journal.pone.0110057.CrossRefPubMedPubMedCentral

Heveran CM, Ortega AM, Cureton A, Clark R, Livingston EW, Bateman TA, et al. Moderate chronic kidney disease impairs bone quality in C57Bl/6J mice. Bone. 2016;86:1–9. https://doi.org/10.1016/j.bone.2016.02.006.CrossRefPubMedPubMedCentral

10.

Iwasaki Y, Kazama JJ, Yamato H, Matsugaki A, Nakano T, Fukagawa M. Altered material properties are responsible for bone fragility in rats with chronic kidney injury. Bone. 2015;81:247–54. https://doi.org/10.1016/j.bone.2015.07.015.CrossRefPubMed

11.

Iwasaki Y, Kazama JJ, Yamato H, Fukagawa M. Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone. 2011;48(6):1260–7. https://doi.org/10.1016/j.bone.2011.03.672.CrossRefPubMed

12.

Stein EM, Silva BC, Boutroy S, Zhou B, Wang J, Udesky J, et al. Primary hyperparathyroidism is associated with abnormal cortical and Trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res. 2013;28(5):1029–40. https://doi.org/10.1002/jbmr.1841.CrossRefPubMedPubMedCentral

13.

Silva BC, Boutroy S, Zhang C, McMahon DJ, Zhou B, Wang J, et al. Trabecular bone score (TBS)--a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2013;98(5):1963–70. https://doi.org/10.1210/jc.2012-4255.CrossRefPubMedPubMedCentral

14.

Wetzsteon RJ, Kalkwarf HJ, Shults J, Zemel BS, Foster BJ, Griffin L, et al. Volumetric bone mineral density and bone structure in childhood chronic kidney disease. J Bone Miner Res. 2011;26(9):2235–44. https://doi.org/10.1002/jbmr.427.CrossRefPubMedPubMedCentral

15.

Tsampalieros A, Kalkwarf HJ, Wetzsteon RJ, Shults J, Zemel BS, Foster BJ, et al. Changes in bone structure and the muscle-bone unit in children with chronic kidney disease. Kidney Int. 2013;83(3):495–502. https://doi.org/10.1038/ki.2012.347.CrossRefPubMed

16.

Gentry JWJ, Davenport D, Malluche HH. Serum phosphorus adds to value of serum parathyroid hormone for assessment of bone turnover in renal osteodystrophy. Clin Nephrol. 2016;86(7):9–17.CrossRefPubMed

17.

Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, et al. Cloning and characterization of an extracellular Ca2+−sensing receptor from bovine parathyroid. Nature. 1993;366(6455):575–80.CrossRefPubMed

18.

Newman CL, Chen NX, Smith E, Smith M, Brown D, Moe SM, et al. Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions. Bone. 2015;77:50–6. https://doi.org/10.1016/j.bone.2015.04.021.CrossRefPubMedPubMedCentral

19.

Isakova T, Wahl P, Vargas G, Gutiérrez OM, Scialla J, Xie H, et al. FGF23, PTH and phosphorus metabolism in the chronic renal insufficiency cohort. Kidney Int. 2011;79(12):1370–8. https://doi.org/10.1038/ki.2011.47.CrossRefPubMedPubMedCentral

20.

Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299(4):F882–9. https://doi.org/10.1152/ajprenal.00360.2010.CrossRefPubMed

21.

Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev. 2012;92(1):131–55. https://doi.org/10.1152/physrev.00002.2011.CrossRefPubMedPubMedCentral

22.

Sanchez CP, Salusky IB, Kuizon BD, Abdella P, Juppner H, Goodman WG. Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney Int. 1998;54(6):1879–87. https://doi.org/10.1046/j.1523-1755.1998.00199.x.CrossRefPubMed

23.

Yu H, Watt H, Kesavan C, Johnson PJ, Wergedal JE, Mohan S. Lasting consequences of traumatic events on behavioral and skeletal parameters in a mouse model for post-traumatic stress disorder (PTSD). PLoS One. 2012;7(8):e42684. https://doi.org/10.1371/journal.pone.0042684.CrossRefPubMedPubMedCentral

24.

Masinde GL, Li X, Gu W, Wergedal J, Mohan S, Baylink DJ. Quantitative trait loci for bone density in mice: the genes determining total skeletal density and femur density show little overlap in F2 mice. Calcif Tissue Int. 2002;71(5):421–8. https://doi.org/10.1007/s00223-001-1113-z.CrossRefPubMed

25.

Yu H, Watt H, Kesavan C, Mohan S. The negative impact of single prolonged stress (SPS) on bone development in mice. Stress (Amsterdam, Netherlands). 2013;16(5):564–70. https://doi.org/10.3109/10253890.2013.806908.CrossRef

26.

Kesavan C, Mohan S. Bone mass gained in response to external loading is preserved for several weeks following cessation of loading in 10 week C57BL/6J mice. J Musculoskelet Neuronal Interact. 2010;10(4):274–80.PubMed

27.

Cheng S, Xing W, Pourteymoor S, Schulte J, Mohan S. Conditional deletion of Prolyl Hydroxylase domain-containing protein 2 (Phd2) gene reveals its essential role in Chondrocyte function and Endochondral bone formation. Endocrinology. 2016;157(1):127–40. https://doi.org/10.1210/en.2015-1473.CrossRefPubMed

28.

Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. Standardized nomenclature, symbols, and units for bone Histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry nomenclature committee. J Bone Miner Res. 2013;28(1):2–17. https://doi.org/10.1002/jbmr.1805.CrossRefPubMedPubMedCentral

29.

Hopper TA, Wehrli FW, Saha PK, Andre JB, Wright AC, Sanchez CP, et al. Quantitative microcomputed tomography assessment of intratrabecular, intertrabecular, and cortical bone architecture in a rat model of severe renal osteodystrophy. J Comput Assist Tomogr. 2007;31(2):320–8.CrossRefPubMed

30.

Negri A, Lombas C, Cuevas C, Schiavelli R, Bogado C, Zanchetta J, Evaluation of cortical bone by peripheral quantitative computed tomography in renal transplant recipients. Transplant Proc. 2005;37(2):1020–22. Elsevier.

31.

Neves KR, Graciolli FG, dos Reis LM, Pasqualucci CA, Moyses RM, Jorgetti V. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int. 2004;66(6):2237–44. https://doi.org/10.1111/j.1523-1755.2004.66013.x.CrossRefPubMed

32.

Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Medscape Womens Health. 2000;5(2):5.PubMed

33.

Takenaka T, Inoue T, Miyazaki T, Hayashi M, Suzuki H. Xeno-Klotho inhibits parathyroid hormone signaling. J Bone Miner Res. 2016;31(2):455–62. https://doi.org/10.1002/jbmr.2691.CrossRefPubMed

34.

Hercz G. Regulation of bone remodeling: impact of novel therapies. Semin Dial. 2001;14(1):55–60.CrossRefPubMed

35.

Mazzaferro S, Tartaglione L, Rotondi S, Pasquali M. Interaction between vitamin D and Calcimimetics in chronic kidney disease. In: Ureña Torres PA, Cozzolino M, Vervloet MG, editors. Vitamin D in chronic kidney disease. Cham: Springer International Publishing; 2016. p. 537–62.CrossRef

36.

Stubbs JR, He N, Idiculla A, Gillihan R, Liu S, David V, et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res. 2012;27(1):38–46. https://doi.org/10.1002/jbmr.516.CrossRefPubMedPubMedCentral

37.

Prie D, Friedlander G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin J Am Soc Nephrol. 2010;5(9):1717–22. https://doi.org/10.2215/cjn.02680310.CrossRefPubMed

38.

Olauson H, Lindberg K, Amin R, Jia T, Wernerson A, Andersson G, et al. Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol. 2012;23(10):1641–51. https://doi.org/10.1681/asn.2012010048.CrossRefPubMedPubMedCentral

39.

Sakan H, Nakatani K, Asai O, Imura A, Tanaka T, Yoshimoto S, et al. Reduced renal alpha-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS One. 2014;9(1):e86301. https://doi.org/10.1371/journal.pone.0086301.CrossRefPubMedPubMedCentral

40.

Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281(10):6120–3. https://doi.org/10.1074/jbc.C500457200.CrossRefPubMedPubMedCentral

41.

Saji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, Sakaguchi T, et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol. 2009;111(4):59–66. https://doi.org/10.1159/000210389.CrossRef

42.

Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int. 2010;21(11):1853–61. https://doi.org/10.1007/s00198-009-1142-4.CrossRefPubMed

43.

Drake MT, Khosla S. Hormonal and systemic regulation of sclerostin. Bone. 2016;96:8–17. https://doi.org/10.1016/j.bone.2016.12.004.

44.

Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146(11):4577–83. https://doi.org/10.1210/en.2005-0239.CrossRefPubMed

45.

Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2016;96:29–37. https://doi.org/10.1016/j.bone.2016.10.007.

46.

Gori F, Lerner U, Ohlsson C, Baron R. A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures. BoneKEy Reports. 2015;4:669. https://doi.org/10.1038/bonekey.2015.36.CrossRefPubMedPubMedCentral

47.

Carrillo-López N, Panizo S, Alonso-Montes C, Román-García P, Rodríguez I, Martínez-Salgado C, et al. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int. 2016;90(1):77–89. https://doi.org/10.1016/j.kint.2016.01.024.CrossRefPubMed

48.

Saracyn M, Czarzasta K, Brytan M, Murawski P, Lewicki S, Ząbkowski T, et al. Role of nitric oxide pathway in development and progression of chronic kidney disease in rats sensitive and resistant to its occurrence in an experimental model of 5/6 Nephrectomy. Med Sci Monit. 2017;23:4865–73. https://doi.org/10.12659/MSM.903820.CrossRefPubMedPubMedCentral

49.

Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis. 1995;26(5):861–5. doi:https://doi.org/10.1016/0272-6386(95)90456-5CrossRefPubMed

50.

Kasiske BL, Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res. 1988;62(2):367.CrossRefPubMed

51.

Fratzl P, Gupta HS, Paschalis EP, Roschger P. Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Mater Chem. 2004;14(14):2115–23. https://doi.org/10.1039/B402005G.CrossRef

52.

Bohnert BN, Daniel C, Amann K, Voelkl J, Alesutan I, Lang F, et al. Impact of phosphorus restriction and vitamin D-substitution on secondary hyperparathyroidism in a Proteinuric mouse model. Kidney Blood Press Res. 2015;40(2):153–65.CrossRefPubMed

Title: Cortical and trabecular bone are equally affected in rats with renal failure and secondary hyperparathyroidism
Authors: Nikita M. Bajwa
Cheryl P. Sanchez
Richard C. Lindsey
Heather Watt
Subburaman Mohan
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Nephrology / Issue 1/2018
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-018-0822-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cortical and trabecular bone are equally affected in rats with renal failure and secondary hyperparathyroidism

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Survival of HIV infected patients on maintenance hemodialysis in Cameroon: a comparative study

Effects of pretransplant peritoneal vs hemodialysis modality on outcome of first kidney transplantation from donors after cardiac death

A case of ureteral myeloid sarcoma post-renal transplantation

Simple citrate anticoagulation protocol for low flux haemodialysis

Development of membranoproliferative glomerulonephritis-like glomerulopathy in a patient with neutrophilia resulting from endogenous granulocyte-colony stimulating factor overproduction: a case report

Renal-limited AL amyloidosis – a diagnostic and management dilemma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page